Nobivac FeLV Data Sheet
Presentation
The inactivated vaccine contains 102 μg per ml of purified p45 FeLV-envelope antigen, obtained by genetic recombination of a strain of E. coli. The antigenic suspension is adjuvanted with 0.1 ml of a 3% aluminium hydroxide gel and with 10μg purified extract of Quillaja saponaria.
Uses
For active immunisation of healthy cats to prevent persistent feline leukaemia virus viraemia and any associated clinical signs. The onset of protection begins 2 weeks after immunisation and the duration of protection lasts one year after the primary vaccination course.
Dosage and administration
Shake the vial before use. Administer via the subcutaneous route 1 dose of Nobivac FeLV according to the following protocol.
Basic vaccination scheme
A first injection in cats from minimum 8 weeks of age.
A second injection in cats 3 to 4 weeks later.
Revaccination scheme
Annual revaccination.
Nobivac FeLV can be used to reconstitute 1 dose (1 vial) of Nobivac Tricat immediately prior to use by the addition of the contents of 1 vial (1 ml) Nobivac FeLV.
Contra-indications, warnings, etc.
Since no data have been generated, do not use to vaccinate females during pregnancy and lactation.
Transient mild skin thickening or nodule formation, approximately 5-10 mm in size, may be observed at the injection site and disappear within 2 to 6 weeks without treatment.
Where Nobivac FeLV has been used to reconstitute Nobivac Tricat prior to inoculation, a small, painless nodule at the site of vaccination is frequently observed. It can persist for up to 13 days post inoculation.
In the rare event of hypersensitivity reaction following vaccination, administer an antihistamine, corticosteroid or adrenaline without delay and by the most immediate route.
Occasionally, systemic reactions (hyperthermia, anorexia, lethargy) may occur within one to two days after vaccine administration.
No undesirable effects have been seen after the administration of an overdose of Nobivac FeLV except those indicated above.
The vaccine should be administered in accordance with the usual aseptic conditions for vaccination.
Vaccinate only healthy animals.
It is recommended that animals be treated for intestinal parasites at least 10 days prior to vaccination.
No information is available on the safety and efficacy from the concurrent use of this vaccine with any other except Nobivac Tricat. It is therefore recommended that no vaccine other than Nobivac Tricat should be administered within 14 days before or after vaccination with Nobivac FeLV.
Do not mix with other vaccine/immunological product except Nobivac Tricat.
Operator warnings
In the case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Withdrawal period
Not applicable.
FOR ANIMAL TREATMENT ONLY.
KEEP OUT OF THE REACH AND SIGHT OF CHILDREN.
Pharmaceutical precautions
Store and transport in the original package at a temperature of 4°C ± 2°C and away from light.
Do not freeze.
Keep container in the outer carton.
Any unused product or waste material should be disposed of in accordance with national requirements.
Legal category
POM-V
Package quantities
Cardboard boxes containing 10 or 50 single dose vials of vaccine.
Not all presentations may be marketed.
Further information
Nil.
Marketing Authorisation number
Vm 05653/4059
